Mizutani, Ryuta http://orcid.org/0000-0002-5484-4861
Saiga, Rino http://orcid.org/0000-0001-7427-7764
Yamamoto, Yoshiro http://orcid.org/0000-0002-9067-1208
Uesugi, Masayuki http://orcid.org/0000-0001-6261-9034
Takeuchi, Akihisa http://orcid.org/0000-0001-7693-9928
Uesugi, Kentaro http://orcid.org/0000-0003-2579-513X
Terada, Yasuko
Suzuki, Yoshio
De Andrade, Vincent http://orcid.org/0000-0003-0987-6618
De Carlo, Francesco http://orcid.org/0000-0003-1068-7785
Takekoshi, Susumu http://orcid.org/0000-0001-8815-8643
Inomoto, Chie
Nakamura, Naoya http://orcid.org/0000-0003-4332-5254
Torii, Youta
Kushima, Itaru http://orcid.org/0000-0002-0018-5178
Iritani, Shuji http://orcid.org/0000-0002-4588-4474
Ozaki, Norio http://orcid.org/0000-0002-7360-4898
Oshima, Kenichi
Itokawa, Masanari http://orcid.org/0000-0003-4433-8030
Arai, Makoto http://orcid.org/0000-0003-3400-9815
Funding for this research was provided by:
MEXT | Japan Society for the Promotion of Science (21611009, 25282250, 25610126, 18H04040)
Japan Agency for Medical Research and Development (19dm0107108, JP18dm0107087, JP19dm0107087, JP20dm0107087, JP20dm0207075, JP20dk0307081, JP18dm0107088, JP19dm0107088h0004, JP20dm0107088h0005)
Article History
Received: 9 September 2020
Revised: 7 December 2020
Accepted: 15 December 2020
First Online: 14 January 2021
Conflict of interest
: M.I. and M.A. declare a conflict of interest, being authors of several patents regarding therapeutic use of pyridoxamine for schizophrenia. All other authors declare no conflict of interest.